99 related articles for article (PubMed ID: 1284762)
21. Secondary myelodysplastic syndrome in multiple myeloma--a study of nine patients with an attempt to detect myeloma patients at risk.
Mittelman M; Lewinski UH; Weiss H; Cohen AM; Djaldetti M; Pick AI
Haematologia (Budap); 1994; 26(2):67-74. PubMed ID: 7890264
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
[TBL] [Abstract][Full Text] [Related]
23. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
24. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
25. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes (MDS) in Central Africans.
Mukiibi JM; Paul B
Trop Geogr Med; 1994; 46(1):17-9. PubMed ID: 8165730
[TBL] [Abstract][Full Text] [Related]
28. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
29. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
30. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
31. Transfusions at home in patients with myelodysplastic syndromes.
Niscola P; Tendas A; Giovannini M; Cupelli L; Trawinska MM; Palombi M; Scaramucci L; Brunetti GA; Perrotti A; Neri B; Efficace F; Cartoni C; de Fabritiis P; Mandelli F
Leuk Res; 2012 Jun; 36(6):684-8. PubMed ID: 22336393
[TBL] [Abstract][Full Text] [Related]
32. Gamma-interferon in myelodysplastic syndromes: a pilot study.
Schwarzinger I; Stain C; Bettelheim P; Hinterberger W; Lechner K
Oncology; 1990; 47(4):322-6. PubMed ID: 2114596
[TBL] [Abstract][Full Text] [Related]
33. [Atypical form of hemochromatosis].
Sutulov IuL; Vasin VA
Arkh Patol; 1976; 38(9):58-61. PubMed ID: 1027407
[TBL] [Abstract][Full Text] [Related]
34. [Hemochromatosis with a predominant lesion of the heart].
Iampol'skaia SA
Arkh Patol; 1979; 41(4):58-61. PubMed ID: 444090
[TBL] [Abstract][Full Text] [Related]
35. [Automated screening for transfusionnal hemochromatosis].
Costello R; Huret G; Sappa E; Bergoin-Costello V
Transfus Clin Biol; 2012 Apr; 19(2):57-9. PubMed ID: 22503459
[TBL] [Abstract][Full Text] [Related]
36. [Successful treatment using iron depletion phlebotomy combined with recombinant erythropoietin after allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by secondary hemochromatosis].
Shinjo K; Takeshita A; Naito K; Ohnishi K; Hirabayashi N; Ohno R
Rinsho Ketsueki; 2001 Jul; 42(7):571-4. PubMed ID: 11524849
[TBL] [Abstract][Full Text] [Related]
37. The pathology of the liver in hemochromatosis.
Powell LW; Kerr JF
Pathobiol Annu; 1975; 5():317-37. PubMed ID: 1196674
[No Abstract] [Full Text] [Related]
38. Causes of death in 2877 patients with myelodysplastic syndromes.
Nachtkamp K; Stark R; Strupp C; Kündgen A; Giagounidis A; Aul C; Hildebrandt B; Haas R; Gattermann N; Germing U
Ann Hematol; 2016 May; 95(6):937-44. PubMed ID: 27025507
[TBL] [Abstract][Full Text] [Related]
39. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.
DeZern AE; Binder G; Rizvi S; Corvino FA; Arikian SR; Surinach A; Lee J; Smith BD
Leuk Lymphoma; 2017 Nov; 58(11):2649-2656. PubMed ID: 28482722
[TBL] [Abstract][Full Text] [Related]
40. [Irreversible acute heart failure caused by cardiac hemochromatosis secondary to multiple transfusions].
Martí V; Guarinos J; Aminian N; Guillaumet E; Domínguez de Rozas JM
Rev Med Chil; 2002 Apr; 130(4):430-2. PubMed ID: 12090109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
